Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | AGXT | P21549 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31570764 | 1.00 | TDP1 (0.68) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL5701220 | 0.92 | TDP1 (0.68) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL38652291 | 0.90 | TDP1 (0.66) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL5701129 | 0.90 | TDP1 (0.66) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL20110893 | 0.89 | TDP1 (0.82) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL10526722 | 0.88 | TDP1 (0.63) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL16902851 | 0.87 | TDP1 (0.87) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL29429997 | 0.85 | TDP1 (0.76) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL8565990 | 0.85 | TDP1 (0.76) | TDP1KDM4EMAPK1AGXTNPC1 | |
| SCHEMBL1859481 | 0.85 | TDP1 (0.76) | TDP1KDM4EMAPK1AGXTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717466-A1 | COMPOUNDS FOR SEPARATION OF RARE EARTH ELEMENTS AND S-, P-, D- METALS, METHOD OF SEPARATION, AND USE THEREOF | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2020-10-07 | — | — | EP | disclosed |
| US-20180118671-A1 | BETA-NAPHTHOL ETHER SULFONATES, PROCESSES FOR PREPARING THEM AND USE THEREOF AS BRIGHTNESS IMPROVERS | BASF SE (DE) | 2018-05-03 | — | — | US | disclosed |
| CN-106748825-A | A kind of synthesis of Dapoxetine hydrochloride, resolving and purifying and salifying method | 聊城大学 | 2017-05-31 | — | — | CN | disclosed |
| CN-101367739-B | Preparation of N,N-dimethyl-1-phenyl-3-(1-naphthoxy) propanamine | TAIZHOU VOCATIONAL & TECHNICAL COLLEGE | 2013-02-13 | — | — | CN | disclosed |
| CN-101367739-A | Preparation of N,N-dimethyl-1-phenyl-3-(1-naphthoxy) propanamine | TAIZHOU VOCATIONAL & TECHNICAL (CN) | 2009-02-18 | — | — | CN | disclosed |
| CN-100447126-C | Omega substituted naphthyloxy-amino alkane den-ivative used as anti-hyperglycaemia agent and its preparation therefor | COUNCIL SCIENT IND RES (IN) | 2008-12-31 | — | — | CN | disclosed |
| CN-1894200-A | Omega-substituted naphthyloxy amino alkane derivatives as antihyperglycemic agents and preparation thereof | COUNCIL SCIENT IND RES (IN) | 2007-01-10 | — | — | CN | disclosed |
| EP-1682484-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-26 | — | — | EP | disclosed |
| US-7081465-B2 | Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-25 | — | — | US | disclosed |
| WO-2005042465-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-05-12 | — | — | WO | disclosed |
| US-20040192688-A1 | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2004-09-30 | — | — | US | disclosed |
| EP-1175400-A1 | RENIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000064873-A1 | RENIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-11-02 | — | — | WO | disclosed |
| US-4053621-A | 1-[2-(βNaphthyloxy)ethyl]-3-methylpyrazolone-(5) and antithrombotic and antithrombolytic compositions and methods utilizing them | BAYER AKTIENGESELLSCHAFT (DT) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118671-A1 | BETA-NAPHTHOL ETHER SULFONATES, PROCESSES FOR PREPARING THEM AND USE THEREOF AS BRIGHTNESS IMPROVERS | LBR, IK, NES | TDP1 3855/4885KDM4E 4380/4885MAPK1 1775/4885 |
| US-20040192688-A1 | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | APOB, LIPC, FABP3 | TDP1 2757/4885KDM4E 2830/4885MAPK1 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.